Economic evaluation of Jintiange capsule in the treatment of postmenopausal osteoporosis
Objective:To evaluate the cost-effectiveness of Jintiange Capsule and Xianlinggubao Capsule for the treatment of postmenopausal women with osteoporosis.Methods:A multicenter,prospective,observational cohort study was carried out to collect information about female patients with osteoporosis who had been naturally menopausal for more than one year.The patients were divided into two groups:the Jintiange capsule combined with bisphosphonates group(Jintiange group)and the Xianlinggubao capsule combined with bisphosphonates group(Xianlinggubao group).The patients were followed up for observation.Based on the healthcare system perspective in China,a propensity score matching method was used to control for confounders and pharmacoeconomic evaluation of the two treatment regimens was performed.Results:The Jintiange group yielded an additional 0.016 QALYs and an additional cost of 822 yuan,so the ICER was 51 375 yuan·QALY-1,which was lower than China's per capita GDP in 2022.Conclusion:Jintiange capsule combined with bisphosphonates group is likely to be a cost-effective treatment compared with Xianlinggubao capsule plus bisphosphonates group for the treatment of postmenopausal osteoporosis.
NETL
NSTL
万方数据
